Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications.
J Mol Cell Cardiol
; 164: 69-82, 2022 03.
Article
en En
| MEDLINE
| ID: mdl-34838588
ABSTRACT
The global propagation of SARS-CoV-2 leads to an unprecedented public health emergency. Despite that the lungs are the primary organ targeted by COVID-19, systemic endothelial inflammation and dysfunction is observed particularly in patients with severe COVID-19, manifested by elevated endothelial injury markers, endotheliitis, and coagulopathy. Here, we review the clinical characteristics of COVID-19 associated endothelial dysfunction; and the likely pathological mechanisms underlying the disease including direct cell entry or indirect immune overreactions after SARS-CoV-2 infection. In addition, we discuss potential biomarkers that might indicate the disease severity, particularly related to the abnormal development of thrombosis that is a fatal vascular complication of severe COVID-19. Furthermore, we summarize clinical trials targeting the direct and indirect pathological pathways after SARS-CoV-2 infection to prevent or inhibit the virus induced endothelial disorders.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Endotelio Vascular
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Etiology_studies
Idioma:
En
Revista:
J Mol Cell Cardiol
Año:
2022
Tipo del documento:
Article
País de afiliación:
China